Johnson & Johnson CEO Joaquin Duato is betting on technology and artificial intelligence to transform patient care, CNBC reported March 30.
The company's medtech business, which saw a 16 percent revenue increase in 2021 compared to 2020, even as COVID-19 limited elective procedures, is causing the new CEO to bet on AI to create advancements in surgery.
"I see a future in which all medical devices would be smarter, connected to the cloud, being able to provide data to the surgeons for them to be able to in real time deliver better surgical outcomes," Mr. Duato told CNBC.
In 2021, the company invested more than $2 billion in innovation and spinned off its consumer health business from its biotech and medical technology to form two companies.
The aim was to create a separate public company dedicated to medical devices and pharmaceuticals.
Mr. Duato, who also served as the company's former interim CIO, said that role gave him insights into how artificial intelligence and automation can make surgery smarter, which is why he believes that technology will be at the forefront of surgical techniques that transform healthcare.